EA202090568A1 - Составы копанлисиба - Google Patents
Составы копанлисибаInfo
- Publication number
- EA202090568A1 EA202090568A1 EA202090568A EA202090568A EA202090568A1 EA 202090568 A1 EA202090568 A1 EA 202090568A1 EA 202090568 A EA202090568 A EA 202090568A EA 202090568 A EA202090568 A EA 202090568A EA 202090568 A1 EA202090568 A1 EA 202090568A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- copanlisib
- stable
- bulk solution
- lyophilization
- copanlisibe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к способу получения стабильного, содержащего копанлисиб, водного нерасфасованного раствора, пригодного для лиофилизации и для терапевтического применения; стабильному, содержащему копанлисиб, нерасфасованному раствору повышенной растворимости, который непосредственно подходит для лиофилизации; способу лиофилизации такого содержащего копанлисиб водного нерасфасованного раствора; стабильному, лиофилизированному, содержащему копанлисиб твердому веществу, в частности порошку или брикету, в особенности содержащему терапевтическую дозу копанлисиба в одной или двух емкостях, в особенности в одной запечатанной емкости; к способу восстановления такого лиофилизата и стабильному, восстановленному, содержащему копанлисиб раствору повышенной растворимости, пригодному для дальнейшего разбавления и для терапевтического применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17207771.1A EP3498266A1 (en) | 2017-12-15 | 2017-12-15 | Formulations of copanlisib |
PCT/EP2018/073965 WO2019048527A1 (en) | 2017-09-08 | 2018-09-06 | COPANLISIB FORMULATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090568A1 true EA202090568A1 (ru) | 2020-07-08 |
Family
ID=60781613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090568A EA202090568A1 (ru) | 2017-12-15 | 2018-09-06 | Составы копанлисиба |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3498266A1 (ru) |
EA (1) | EA202090568A1 (ru) |
PT (1) | PT3678644T (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112569340A (zh) * | 2020-12-31 | 2021-03-30 | 苏州素仕生物科技有限公司 | 一种无菌布舍瑞林注射液及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1549652B1 (en) | 2002-09-30 | 2008-10-22 | Bayer HealthCare AG | Fused azole-pyrimidine derivatives |
AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
TN2018000272A1 (en) * | 2016-02-01 | 2020-01-16 | Bayer Pharma AG | Copanlisib biomarkers |
-
2017
- 2017-12-15 EP EP17207771.1A patent/EP3498266A1/en not_active Withdrawn
-
2018
- 2018-09-06 EA EA202090568A patent/EA202090568A1/ru unknown
- 2018-09-06 PT PT187621073T patent/PT3678644T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
PT3678644T (pt) | 2023-07-25 |
EP3498266A1 (en) | 2019-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202002378B (en) | Formulations of copanlisib | |
PH12017500844B1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
PH12019500862A1 (en) | Novel cd47 monoclonal antibodies and uses thereof | |
PH12014501988A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
WO2018083087A3 (en) | Binding proteins | |
TN2014000431A1 (en) | Antibody formulatoin | |
MX2018015749A (es) | Formulacion de una vacuna peptidica. | |
MX2017005575A (es) | Formulacion farmaceutica de anticuerpos anti-tnf alfa. | |
EA201691478A1 (ru) | Новый полисахарид и его применения | |
EA200870264A1 (ru) | Композиция антител | |
EA202090731A1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
JP2017531682A5 (ru) | ||
EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
PH12016501877A1 (en) | Lypophilized factor ix formulations | |
EA202090568A1 (ru) | Составы копанлисиба | |
EA201790833A1 (ru) | Сухой порошкоообразный состав | |
EA202191515A1 (ru) | Фармацевтическая композиция, содержащая апиксабан | |
MX2021007047A (es) | Formulaciones de anticuerpos. | |
GB201122430D0 (en) | Reconstitution method for high concentration dry protein formulation | |
AR112753A1 (es) | Formulaciones de copanlisib | |
MX2015009141A (es) | Formulaciones de albu-bche, preparacion y usos de las mismas. | |
AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
EA201800311A1 (ru) | Способ получения фармацевтической композиции, содержащей бортезомиб, продукт способа |